| | |
每股和
随行 搜查令 |
| |
共计
|
| ||||||
公开发行价格
|
| | | $ | 1.5000 | | | | | $ | 10,000,000.50 | | |
承保折扣及佣金(1)
|
| | | $ | 0.0975 | | | | | $ | 650,000.03 | | |
出售给Ekso仿生学控股公司。(费用前)
|
| | | $ | 1.4025 | | | | | $ | 9,350,000.47 | | |
|
销售线索-运营经理
|
| |
联合簿记管理器
|
|
|
康托
|
| |
SunTrust Robinson Humphrey
|
|
| | |
页
|
| |||
关于此“招股说明书”副刊
|
| | | | S-ii | | |
前瞻性陈述
|
| | | | S-iv | | |
招股说明书补充摘要
|
| | | | S-1 | | |
The Offering
|
| | | | S-3 | | |
Risk Factors
|
| | | | S-5 | | |
Use of Proceeds
|
| | | | S-9 | | |
Capitalization
|
| | | | S-10 | | |
Dilution
|
| | | | S-11 | | |
Dividend Policy
|
| | | | S-12 | | |
我们提供的证券的说明
|
| | | | S-13 | | |
美国联邦所得税的重大后果
|
| | | | S-15 | | |
Underwriting
|
| | | | S-21 | | |
Notice to Investors
|
| | | | S-25 | | |
Legal Matters
|
| | | | S-30 | | |
Experts
|
| | | | S-30 | | |
在其中可以找到详细信息
|
| | | | S-31 | | |
通过引用纳入某些文档
|
| | | | S-32 | | |
| | |
页
|
| |||
About This Prospectus
|
| | | | ii | | |
Prospectus Summary
|
| | | | 1 | | |
Risk Factors
|
| | | | 3 | | |
关于前瞻性陈述的特别说明
|
| | | | 3 | | |
About Ekso Bionics
|
| | | | 4 | | |
Use of Proceeds
|
| | | | 4 | | |
Plan of Distribution
|
| | | | 5 | | |
普通股票的
说明
|
| | | | 8 | | |
优先股的说明
|
| | | | 8 | | |
Description of Warrants
|
| | | | 10 | | |
Description of Rights
|
| | | | 12 | | |
Description of Units
|
| | | | 13 | | |
内华达州法律和公司章程的某些规定
|
| | | | 14 | | |
Legal Matters
|
| | | | 16 | | |
Experts
|
| | | | 16 | | |
在其中可以找到详细信息
|
| | | | 16 | | |
通过引用合并文档
|
| | | | 16 | | |
| | |
截至2019年3月31日
|
| |||||||||
| | |
实际
|
| |
经过调整
|
| ||||||
| | |
(单位:千,面值除外)
和每共享数据) |
| |||||||||
现金及现金等价物
|
| | | $ | 9,236 | | | | | $ | 18,371 | | |
长期债务净额
|
| | | $ | 4,426 | | | | | $ | 4,426 | | |
股东权益: | | | | | | | | | | | | | |
可转换优先股,票面价值0.001美元;核准10 000股;未发行和流通
|
| | | | — | | | | | | — | | |
普通股,面值0.001美元;核定股票141,429股;实际发行和流通股67,529股,经调整后,已发行和流通股74,195股
|
| | | | 68 | | | | | | 74 | | |
额外实收资本
|
| | | | 182,107 | | | | | | 191,236 | | |
累计其他全面收入(损失)
|
| | | | 56 | | | | | | 56 | | |
累积赤字
|
| | | | (177,697) | | | | | | (177,697) | | |
股东权益总额
|
| | | | 4,534 | | | | | | 13,669 | | |
资本化总额
|
| | | $ | 8,960 | | | | | $ | 18,095 | | |
|
|
每股公开发行价格及随附认股权证(一)
|
| | | | | | | | | $ | 1.50 | | |
|
截至2019年3月31日的每股有形账面净值
|
| | | $ | 0.06 | | | | | | | | |
|
可归因于新投资者的每股增长
|
| | | $ | 0.12 | | | | | | | | |
|
经调整的每股有形账面净值于2019年3月31日生效后
这个产品 |
| | | | | | | | | $ | 0.18 | | |
|
向购买本公司普通股及认股权证的新投资者摊薄每股股份
|
| | | | | | | | | $ | 1.32 | | |
包销商
|
| |
股份数
|
| |
数量
随附认股权证 |
| ||||||
康托菲茨杰拉德公司
|
| | | | 4,333,334 | | | | | | 4,333,334 | | |
SunTrust Robinson Humphrey公司
|
| | | | 2,333,333 | | | | | | 2,333,333 | | |
共计
|
| | | | 6,666,667 | | | | | | 6,666,667 | | |
|
| | |
每股和
随行 权证 |
| |
共计
|
| ||||||
公开发行价格
|
| | | $ | 1.5000 | | | | | $ | 10,000,000.50 | | |
承保折扣及佣金
|
| | | $ | 0.0975 | | | | | $ | 650,000.03 | | |
在支出之前付给我们的收入
|
| | | $ | 1.4025 | | | | | $ | 9,350,000.47 | | |
| | |
页
|
| |||
About This Prospectus
|
| | | | ii | | |
Prospectus Summary
|
| | | | 1 | | |
Risk Factors
|
| | | | 3 | | |
关于前瞻性陈述的特别说明
|
| | | | 3 | | |
About Ekso Bionics
|
| | | | 4 | | |
Use of Proceeds
|
| | | | 4 | | |
Plan of Distribution
|
| | | | 5 | | |
普通股票的
说明
|
| | | | 8 | | |
优先股的说明
|
| | | | 8 | | |
Description of Warrants
|
| | | | 10 | | |
Description of Rights
|
| | | | 12 | | |
Description of Units
|
| | | | 13 | | |
内华达州法律和公司章程的某些规定
|
| | | | 14 | | |
Legal Matters
|
| | | | 16 | | |
Experts | | | | | 16 | | |
在其中可以找到详细信息
|
| | | | 16 | | |
通过引用合并文档
|
| | | | 16 | | |
|
销售线索-运营经理
|
| |
联合簿记管理器
|
| | | |
|
康托
|
| |
SunTrust Robinson Humphrey
|
| |